A Study to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 60 Years or Above (Complementary Study to DAN-RSV)First published 04/06/2025 Last updated 04/06/2025 EU PAS number: EUPAS1000000480StudyPlanned
Sine Hojlund Christensen sine.hojlund.christensen@regionh.dkStudy contactsine.hojlund.christensen@regionh.dk